| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5351c62aee4203f2be2944f21a6def2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2030-8818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2030-8813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6812 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-88 |
| filingDate |
2017-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_323ae9eaecbe4bb03be62fc760b4c796
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a6b986b38c2889cf08adb249a0c5318
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17cbbb522348af6dcf146298a5ad83ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_444d30569092bf1b7e2a5fca05d510fb |
| publicationDate |
2019-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20190033382-A |
| titleOfInvention |
A method and kit for assessing risk of breast cancer using metabolite profiling |
| abstract |
The present invention relates to a diagnostic method for evaluating a breast cancer-related risk based on a specific biomarker, comprising the steps of: (a) obtaining a biological sample from a subject; (b) leucine (leucine), tyrosine (tyrosine), arachidonic acid (arachidonic acid), prostaglandin J 2 (prostaglandin J 2), prostaglandin E 2 (prostaglandin E 2) and gamma-linolenic acid (γ-linolenic acid) in the biological sample Measuring at least one metabolite concentration selected from the group consisting of: And (c) comparing the level of the measured metabolite to a measurement value in a normal control sample. A method for assessing the prognosis or risk of breast cancer is provided. |
| priorityDate |
2017-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |